Loading
A phase 2 trial of Sacituzumab tirumotecan in thymoma and thymic carcinoma, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma is a phase 2 interventional study registered as NCT07324629 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 30 participants planned, started 2026-03-13 and due to reach its primary completion in 2028-04. Interventions recorded: Sacituzumab tirumotecan.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Thymic carcinoma, Thymoma and thymic carcinoma and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Thymic carcinoma, Thymoma and thymic carcinoma and the tag pipeline.